Chinese expert consensus on polymyxins in the clinical practice.
10.3760/cma.j.issn.2095-4352.2019.10.003
- Author:
CHINESE RESEARCH HOSPITAL ASSOCIATION OF CRITICAL CARE MEDICINE
;
CHINESE RESEARCH HOSPITAL ASSOCIATION OF EVIDENCE BASE AND TRANSLATIONAL INFECTIOUS DISEASES
- Publication Type:Journal Article
- MeSH:
Anti-Bacterial Agents;
China;
Consensus;
Drug-Related Side Effects and Adverse Reactions;
Gram-Negative Bacterial Infections;
Humans;
Polymyxins
- From:
Chinese Critical Care Medicine
2019;31(10):1194-1198
- CountryChina
- Language:Chinese
-
Abstract:
Polymyxin, a polypeptide antibiotic, derived from the culture of bacillus polymucilis, was introduced in the 1950s and used in clinical practice, but was replaced by safer antimicrobials due to its renal toxicity. In the recent years, with the increasing incidence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacilli infections, polymyxin is reintroduced into the clinic because it is assumed an important role in the treatment of MDR infections and XDR infections. In order to regulate the clinical applications of polymyxin, we organized experts in relevant fields to develop expert consensus on polymyxin for reference, including parameters like pharmacokinetics and pharmacodynamics, dosage and usage, contraindications and relative contraindications, clinical applications and adverse reactions.
